(redirected from Pulmicort Turbuhaler)
Also found in: Dictionary.
Related to Pulmicort Turbuhaler: Symbicort


a glucocorticoid antiinflammatory agent administered by inhalation to treat asthma, intranasally to treat allergic rhinitis and other inflammatory nasal conditions, rectally to treat ulcerative colitis, and orally to treat Crohn's disease.


Budenofalk (UK), Easyhaler Budesonide (UK), Entocort CR (UK), Entocort EC, Entocort Enema (UK), Novolizer Budesonide (UK), Pulmicort Flexhaler, Pulmicort Respules, Rhinocort Aqua

Pharmacologic class: Corticosteroid (inhalation)

Therapeutic class: Antiasthmatic, steroidal anti-inflammatory

Pregnancy risk category B (intranasal, inhalation); C (oral)

FDA Box Warning

• Pulmicort Respules is meant only for inhalation by compressed air-driven jet nebulizers (not ultrasonic devices). It must not be injected. Read patient instructions before using.


Decreases inflammation by inhibiting migration of inflammatory mediators to injury site, where it reverses dilation and increases vessel permeability. Also decreases plasma exudation and mucus secretions within airway.


Capsules (extended-release): 3 mg

Inhalation powder: 90 mcg (Pulmicort Flexhaler), 180 mcg (Pulmicort Flex-haler)

Inhalation suspension (Respules): 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/ml

Nasal spray: 32 mcg/metered spray (7-g canister)

Indications and dosages

Maintenance treatment of asthma as prophylactic therapy

Adults: 360 mcg (powder for oral inhalation) inhaled b.i.d. For some patients, 180 mcg inhaled b.i.d. may be appropriate. Maximum dosage is 720 mcg b.i.d.

Children ages 6 to 17: 180 mcg (powder for oral inhalation) inhaled b.i.d. For some patients, dosage of 360 mcg inhaled b.i.d. may be appropriate. Maximum dosage is 360 mcg b.i.d.

Seasonal or perennial allergic rhinitis

Adults and children ages 6 and older: Two sprays in each nostril in morning and evening, or four sprays in each nostril in morning. Maintenance dosage is fewest number of sprays needed to control symptoms.

Mild to moderate active Crohn's disease involving ileum, ascending colon, or both

Adults: 9 mg P.O. daily for up to 8 weeks. For recurring episodes of active Crohn's disease, 8-week course can be repeated and tapered to 6 mg P.O. daily for 2 weeks before complete cessation.

Dosage adjustment

• Moderate to severe hepatic disease


• Hypersensitivity to drug
• Status asthmaticus


Use cautiously in:
• renal disease, hepatic disease, heart failure, active untreated infections, systemic infections, hypertension, osteoporosis, diabetes mellitus, glaucoma, underlying immunosuppression, hypothyroidism, diverticulitis, nonspecific ulcerative colitis, recent intestinal anastomoses, thromboembolic disorders, seizures, myasthenia gravis, ocular herpes simplex infection
• patients receiving concurrent systemic corticosteroids
• pregnant or breastfeeding patients
• children younger than age 6.


• If patient also uses a bronchodilator, give that drug at least 15 minutes before budesonide.
• Know that using a spacer reduces risk of candidiasis and hoarseness.
• Make sure patient swallows capsules whole without crushing or chewing them.

Adverse reactions

CNS: headache, nervousness, depression, euphoria, psychoses, increased intracranial pressure

CV: hypertension, Churg-Strauss syndrome, thrombophlebitis, thromboembolism

EENT: cataracts, nasal congestion, nasal burning or dryness, epistaxis, perforated nasal septum, hoarseness, nasopharyngeal and oropharyngeal fungal infections

GI: nausea, vomiting, peptic ulcers, anorexia, esophageal candidiasis, dry mouth

Metabolic: hyperglycemia, decreased growth (in children), cushingoid appearance (moon face, buffalo hump), adrenal suppression or insufficiency

Musculoskeletal: muscle wasting, muscle pain, osteoporosis, aseptic joint necrosis

Respiratory: cough, wheezing, rebound congestion, bronchospasm

Skin: facial edema, rash, petechiae, contact dermatitis, acne, bruising, hirsutism, urticaria

Other: bad taste, anosmia, weight gain or loss, increased susceptibility to infection, angioedema, hypersensitivity reaction


Drug-drug.Amphotericin B, mezlocillin, piperacillin, thiazide and loop diuretics, ticarcillin: additive hypokalemia

Digoxin: increased risk of digoxin toxicity

Erythromycin, indinavir, itraconazole, ketoconazole, ritonavir, saquinavir: increased blood level and effects of budesonide

Fluoroquinolones: increased risk of tendon rupture

Hormonal contraceptives: blockage of budesonide metabolism

Insulin, oral hypoglycemics: increased budesonide requirement

Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse effects from budesonide

Nonsteroidal anti-inflammatory drugs (including aspirin): increased risk of adverse GI effects

Phenobarbital, phenytoin, rifampin: decreased budesonide efficacy

Somatrem, somatropin: decreased response to budesonide

Drug-food.Grapefruit, grapefruit juice: increased blood level and effects of budesonide

High-fat meal: delayed peak budesonide concentration

Patient monitoring

• Monitor respiratory status to evaluate drug efficacy.

Stay alert for hypersensitivity reactions, especially angioedema.
• Evaluate liver function test results.
• Periodically observe patient for proper inhaler use.
• Assess oral cavity for infection.

Patient teaching

• Teach patient proper use of inhaler.
• Tell patient to swallow capsules whole without crushing or chewing them.

Instruct patient to contact prescriber immediately if he develops itching, rash, fever, swelling of face and neck, or difficulty breathing.
• Encourage patient to document medication use and his response in diary.
• Advise patient to report signs and symptoms of fungal infections of mouth.
• Tell female patient to inform prescriber if she is pregnant or plans to become pregnant.
• Caution patient to avoid exposure to chickenpox and measles, if possible.
• Emphasize importance of rinsing mouth after each inhaler treatment and washing and drying inhaler thoroughly after each use.
• Instruct patient to avoid high-fat meals, grapefruit, and grapefruit juice.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and foods mentioned above.


/bu·des·o·nide/ (bu-des´ah-nīd) an antiinflammatory glucocorticoid used to treat allergic rhinitis, bronchial asthma, nasal inflammation, ulcerative colitis, and Crohn's disease.


A corticosteroid used in the treatment of asthma, allergic rhinitis, ulcerative colitis, and Crohn's disease.


a nasal corticosteroid antiinflammatory agent. It is available under the brand name Pulmicort as a turboinhaler (used in the mouth) and for use in nebulizers.
indications It is prescribed in the management of symptoms of seasonal or perennial allergic rhinitis or perennial nonallergic rhinitis. Nebulizer solutions are used for the treatment of asthma in children.
contraindications The drug should not be given to patients who have an allergic reaction to the drug or to any of its components or to patients with an untreated infection of the mucous membranes.
adverse effects The side effects most often reported include nasal or throat irritation, stinging, burning, or dryness in the respiratory system, nosebleeds, sneezing, and congestion.


A nebulisable synthetic glucocorticosteroid, structurally related to 16α-hydroxyprednisolone, which has high topical anti-inflammatory activity, low systemic activity and enhanced receptor-binding activity, but more rapid presystemic metabolism than other corticosteroids.

Coup, asthma, allergic rhinitis, inflammatory colitides—e.g., ulcerative colititis and Crohn’s disease; seasonal or perennial.
Adverse effects
Nasal irritation, sores and bleeding, upset stomach, cough, dry mouth, rash, muscle cramps.


Rhinocort Pharmacology A nebulizable synthetic glucocorticosteroid with high topical antiinflammatory activity, low systemic activity, and enhanced receptor binding activity; nebulized budesonide is used for croup and control of mild asthma, for inflammatory colitides–eg, ulcerative colititis and Crohn's disease, and seasonal or perennial allergic rhinitis. See Allergic rhinitis.


A corticosteroid drug used in a nasal spray for hay fever (allergic rhinitis) or as an inhalant for ASTHMA. Brand names are Entocort, Pulicort and Rhinocort. With EFORMOTEROL (formoterol) it is marketed as Symbicort.

budesonide (byōōdes´ōnīd´),

n brand names: Rhinocort Nasal Inhaler, Pulmicort;
drug class: corticosteroid, synthetic;
action: interacts with steroid cytoplasmic receptors to induce antiinflammatory effects;
uses: management of symptoms of allergic rhinitis in adults and children; perennial nonallergic rhinitis in adults.
References in periodicals archive ?
Pulmicort Turbuhaler is taken once daily with an electronic nebuliser that change liquid medicines into a fine mist for easy breathing in.
Table 6: Budesonide Clickhaler - Assessment Of Adrenal Suppression From Two New Dry Powder Inhaler Formulations Of Budesonide Delivered By Clickhaler Compared With The Pulmicort Turbuhaler
Studies of pregnant women have shown that inhaled budesonide, the active compound in Pulmicort Turbuhaler, does not increase the risk of abnormalities when administered during pregnancy.
Pulmicort Turbuhaler is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older.
Studies of pregnant women have shown that inhaled budesonide, the active compound in both Pulmicort Respules and Pulmicort Turbuhaler, does not increase the risk of abnormalities when administered during pregnancy.
and Pulmicort Turbuhaler, which was launched in 1998 as the first, CFC-free, dry-powdered inhaled corticosteroid.
Studies of pregnant women have shown that Pulmicort Turbuhaler does not increase the risk of abnormalities when administered during pregnancy.
Pulmicort Turbuhaler has been shown to be effective in decreasing chronic airway inflammation, reducing the use of Beta2-agonist medication, commonly known as bronchodilators, and improving daytime and nighttime asthma symptoms.
Based on this trial as well as other supportive studies submitted to the FDA, the agency approved the addition of the simple, once- daily treatment option for Pulmicort Turbuhaler in adults and children six years of age and older with mild to moderate asthma who are well-controlled by an inhaled corticosteroid.
study and other supportive studies submitted to the FDA that demonstrated the safety and effectiveness of Pulmicort Turbuhaler when taken once daily by asthmatics with mild to moderate disease adequately controlled by inhaled corticosteroid medication.
Food and Drug Administration (FDA) for the anti-inflammatory asthma medication Pulmicort Turbuhaler (budesonide inhalation powder).
Food and Drug Administration (FDA) for Pulmicort Turbuhaler, the company's breath-activated dry-powder corticosteroid inhaler.